Intervention type

Phase

Drug names

Primary outcome measures

The relative change of periprosthetic bone mineral density (BMD) in region 7 of Gruen after total hip arthroplasty over 12 months

Secondary outcome measures

1. The relative change of other regions of Gruen over 12 months2. Safety over 12 months

Overall trial start date

01/05/2011

Overall trial end date

30/04/2013

Reason abandoned

Eligibility

Participant inclusion criteria

1. Caucasian male or postmenopausal women2. Age less than or equal to 50 years3. Patients with conventional primary total hip arthroplasty, cementless femoral stem and primary coxarthrosis as indication for total hip arthroplasty

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

126

Participant exclusion criteria

1. Short femoral stem2. Any perioperative complication3. Patient with inflammatory arthropathy4. Impossibility to perform Dual-emission X-ray absorptiometry (DXA)5. Increase risk or history of venous thromboembolism (VTE)6. Known hypersensitivity or contraindication to the study drug or Calperos D3® 7. Concomittant treatments likely to interfere with bone metabolism